Answers are grounded in this paper and cite their sources.
Lu-PSMA-617 are promising theranostics that could improve both diagnostic accuracy and therapeutic efficacy. Advanced clinical studies with immune checkpoint inhibitors (ICIs) have shown limited benefits in PCa, whereas subgroups of PCa with mismatch repair (MMR) or CDK12 inactivation may benefit from ICIs treatment. In this review, we summarized the targeted agents of PCa in clinical trials and their underlying mechanisms, and further discussed their limitations and future directions.
No takes yet. Share an insight, caveat, or question.
He et al. (2022) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: